Fort dignum, TX, August II, MMXXII (Globe Newswire) - TFF PHARMACEUTICALS, Inc. (TFF TFF PHARMACEITICAL PHARMACEADUS PHARMACTADUS PHARMADUS DELIGENTIAE ET PHARMACKST PHARMACE EDIFICATION PHARMACTATION PRORDMENTUM MMXXII Financial Results et Business Iovis. August XI, MMXXII, ad proxima US Financial mercatis.
Management et tenere colloquium vocatio ad 4:30 PM et ad de financial praecessi et providere an update in corporatum et orci developments.Praesentatio et sequitur a Q & sessionem cum investors.
In comitatu et tenere colloquium vocatio in Iovis, August XI, MMXXII at 4:30 PM et ad review orci, corporatum et financial perficientur. Ad iungere colloquium, iungere ad webcast vel horologio unus de his ante incipiens vocationem:
Et vocatio erit quoque esse webcast vivere et potest accessed in TFF PHARMACEUTICALS 'Website, https://tffpharma.com vel directe ad https://viavid.webasts.com/starthere.jsp?ei=1558913&tp_key=43b9453c47. Et vocatio erit quoque esse webcast vivere et potest accessed in TFF PHARMACEUTICALS 'Website, https://tffpharma.com vel directe ad https://viavid.webasts.com/starthere.jsp?ei=1558913&tp_key=43b9453c47. Конференция также будет транслироваться прямом ээире и доступна на веб-Сайте TFF PHARMACEUTICALS https://tffpharma.com или непосредственно на https://viavid.webasts.com/starthere.jsp?ei=1558913&tp_key=43b9453c47. Conference et quoque esse streamed vivere et available in TFF PHARMACEUTICALS Website https://tffpharma.com vel directe ad https://viavid.webasts.com/starthere.jsp?ei=1558913&tp_key=43b9453c47.电话会议还将进行网络直播, 可以在 tff pharmaceuticals 的网站 https://tffpharma.com 或直接访问 https://viavid.webasts.com/starthere.jsp?ei=1558913&tp_key=43b9453c47 访问. TFF PHARMACEUTICALS 的网站 https://tffpharma.com 或直接访问 https://viavid.webasts.com/starthere.jsp?ei=1558913&tp_key34=43 Конференц-Связь также будет транслите и иоступна на веб-Сайте tff pharmaceuticals по Адресу https://tffpharma.com или по Адресу Напрямую по Адресу https://viavid.webasts.com/starthere.jsp?ei=1558913&tp_key=43b9453c47. Conference vocatio erit quoque et in TFF PHARMACEuticals website in https://tffpharma.com vel directe ad https://viavid.webasts.com/starthere.jsp?ei=1558913&tp_key=43b9453c47.Placere visitare Company scriptor website saltem XV minuta antequam vestri appointment ut subcriptio, download quod install omnes requiritur audio software. Et vocatio etiam lusit per mensem in investor fastis sectione de comitatu scriptor website.
De TFF PHARMACEUTICALS tenuis film frigore technology suggestus TFF PHARMACEUTICALS 'patented tenuis film glacians (TFF) Technology concedit existentium componit et novas chemicals ut convertitur in siccis pulveris et in unique proprietatibus et beneficia. In film glacians processum est particulam ipsum processus disposito ad producendum arida pulveris particulas cum proprietatibus ad inspiratione, parentera, nasi, oris, topici et ophthalmic itinera administrationis. Hoc processus potest esse ut develop pulveres ad directam partus ad desideravit situ, ita avoiding systemica administratione problems et meliorem bioavailability, citius improving actum et improvidus salutem et efficaciam. Et facultatem eripere illic directe ad target organa ut pulmones permittit TF Pulmine ad administratum ad minus doses comparari oris formulationibus, reducendo necesse toxicity et latus effectus. Laboratory notitia indicant quod aerodynamic proprietatibus tenui-film gelida pulveris potest eripere usque ad LXXV% of a dose altum in pulmone. Instead nuditate ad calorem, tondendas accentus, aut alias viribus quod potest damnum magis universa therapeutica components ut fragilis biologicis, tenuis-film glaciandit, quod facile est ad aridam, permittit, quod facile est in arida, permittens in therapeutica et temperatus stabilis, permittens magis globally et vaccines . Et beneficia tenuis film glacians potest ad amplio traditional traditio vel in tandem cum altera generatione pharmaceuticals.
De TFF PHARMACEUTICALS TFF PHARMACEUTICALS, Inc. est orci scaena Biopharmaceutical turma, quod utitur patented velox Frigidus technology ut develop et convertere medicinae efficaciam siccis pulveris, ut amplio efficacia, salus et stabilitatem. In comitatu scriptor versatile tenuis film glacians (TFF) Technology Platform habet late applicationem et vertit aliquam medicamento, inter vaccines, parva et magnis moleculis, et inhalantes et meliori, sic et inhalantes et potius est, sic etiam in inhalantes, sic et in inhalantes, sic etiam ut inhalantes. In oculis, nasus et loci cutis. TFF has duo major orci medicamento candidati, voriconzole inspiratione pulveris et tactrolimus inspiratione pulveris, et continues ad expand eius portfolio ut revolutionizare global turmas, academic cum amplis et imperium societates, academicis institutions et imperium societates. TFF Platform est operuit per CXX patentibus edita vel pendente in US et aliis terris. Discere magis de TFF PHARMACEUTICALS et ejus candidatus products, placere visitare comitatu scriptor website ad https://tffpharma.com.
Tutus portum hoc press release habet deinceps-vultus statements de TFF PHARMACEUTICALS, Inc., inter se spem pro continued development of Tacrolimus et voriconAZOLE STFF TFF Pulveres, et in consiliis est ad addere ad suum esse candidatus productum linea. Hi deinceps-vultus statements involvere notum et ignotum metus, incerta et alia factores, quae posset facere re praecessi differre materialiter. Haec factores includit (I) periculum quod societatem non poterit feliciter perfici orci iudiciis aut obtinere premarket approbatione ad eius attrahitur Tacrolmi, VorInCizole et Alioquin Listing a Customer PowerCompe, aut non est currently in consensu vel intellegentia et non est currently in consensu vel intellectus, non est currently in consensu vel intellegentia et non est currently in consensu vel intellegentia et non est currently in consensu vel intellectus, aut non est currently in consensu vel intellegentia cum non est currently in consensu vel intellectus, non est currently in consensu vel intellectus, non est currently in consensu vel intellectus, non est currently in consensu vel intellectus, non est currently in consensu vel intellectus, non est currently in consensu vel intellectus et non est currently in consensu vel intellectus, non est currently in consensum, aut intellectus in aliquo major Pharmaceutical Company ut develop a medicamento et inclusion in TFF Platform, (iv) in comitatu non poterit intrare in tempore commercial pacta cum aliqua tertia pars; Et (v) Alia periculum identified in "Periculum factores" sectionem formam X de comitatu scriptor MMXXI annua fama - k, filed in sec die Martii XXIV, MMXXII. TF in quolibet vel deinceps, respicit. TFF PHARMACEUTICALS assumit et specie disclaims ulla obligatione update vel revise talia ut reflectunt novas circumstantias aut improvisum circumstantias, nisi quod lege requiritur.
TFF Pharmaceuticals Investor Relations Contact: Corey Davis, PhD LifeSci Advisorsscdavis@lifesciadvisors.com 212-915-2577
TFF Pharmaceuticals Media Contact: Gwendolyn SchankerLifeSci Communications(269) 921-3607gschanker@lifescicomms.com
Post tempus: Aug-10-2022